Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

UroGen Pharma (URGN) Long-Term Debt Issuances (2022)

UroGen Pharma (URGN) has disclosed Long-Term Debt Issuances for 1 consecutive years, with $25.0 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Debt Issuances changed N/A year-over-year to $25.0 million, compared with a TTM value of $25.0 million through Sep 2023, down 64.7%, and an annual FY2024 reading of $24.5 million, changed N/A over the prior year.
  • Long-Term Debt Issuances was $25.0 million for Q4 2022 at UroGen Pharma, up from -$38000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $70.8 million in Q1 2022 and bottomed at -$38000.0 in Q2 2022.